In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Funding: Where the Money's At

Executive Summary

The $752 million worth of new funds raised by leading European biotechnology VCs over the past three months suggests that Europe's private biotech market is picking up. But these funds won't simply land in companies' laps. Europe's biotech managers, many of whom have raised funds only during boom times, will have to satisfy increasingly stringent criteria to secure their slice of the pie. Yet although late-stage products and critical mass still top some investors' wish lists, selected platform and early-stage groups capable of rapidly advancing a broad range of compounds into the clinic have also found funding.

You may also be interested in...



Biotech Money, Where Art Thou?

While public biotech funding in the US in 2003 outpaced private funding by more than five to one, the smaller financing picture in Europe tells a different story.

European Biotech M&A: Often Last Resort, but Welcome Nevertheless

Consolidation among Europe's biotech firms is picking up, but less for strategic reasons than simply to secure the cash to survive. Whatever the drivers, though, and however ruthless the concurrent cost- and program cutting, M&A should help create better adapted, bigger companies-something investors have long been calling for. Indeed for most merging companies, M&A is just the first step towards more strategic business-building moves in the near future.

Early M&A: The Secret of Biotech's Success

As a product-focused biotech with two clinical phase cancer compounds ready to out-license, Wilex stands apart from most of its German--and European--peers. It has got to where it is by virtue of tight focus cost control and an early openness to M&A. Wilex now needs to show it can sign the sort of deals it needs to get to the next level.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004794

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel